Gemcitabine for Injection IP 1000mg
GEMLIEVA 1000 MG (Gemcitabine for Injection IP 1000 mg) is a prescription anticancer medication containing Gemcitabine 1000 mg, a widely used chemotherapy medicine indicated for the treatment of various solid tumors and advanced cancers. Gemcitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the DNA replication process of rapidly growing cancer cells, helping to slow or stop their growth and spread.
Cancer develops when abnormal cells multiply uncontrollably and invade surrounding tissues. These malignant cells require continuous DNA synthesis to grow and divide. Gemcitabine disrupts this process by incorporating itself into the DNA of cancer cells and preventing further replication. As a result, cancer cells lose their ability to multiply and eventually die.
GEMLIEVA 1000 MG is widely used in modern oncology and is considered an important treatment option for several types of cancer. It may be administered as a single-agent therapy or combined with other chemotherapy medicines depending on the type of cancer, stage of disease, and treatment objectives determined by the oncologist.
The medicine is commonly prescribed for:
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Ovarian Cancer
Bladder Cancer
Biliary Tract Cancer
Metastatic and Advanced Solid Tumors
Combination Chemotherapy Protocols
Oncology and Specialized Cancer Treatment Programs
Gemcitabine has become a key component of many cancer treatment regimens because of its proven clinical effectiveness and broad therapeutic applications. It is frequently used in patients with advanced disease where long-term disease control and symptom management are important treatment goals.
Manufactured according to stringent pharmaceutical quality standards, GEMLIEVA 1000 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Patients receiving Gemcitabine treatment typically require regular monitoring through blood tests, liver function assessments, kidney evaluations, and routine medical examinations to ensure treatment effectiveness and patient safety.
Due to its established role in cancer therapy, GEMLIEVA 1000 MG remains an essential medicine in modern oncology care worldwide.
View Details
Gemcitabine for Injection IP 200mg
GEMLIEVA RTU 200 MG (Gemcitabine for Injection IP 200 mg) is a prescription anticancer medication containing Gemcitabine 200 mg, a well-established chemotherapy medicine used in the treatment of various solid tumors and advanced cancers. The term RTU (Ready-to-Use) indicates that the formulation is designed for convenient clinical administration, helping healthcare professionals prepare and deliver treatment efficiently while maintaining accuracy and safety.
Gemcitabine belongs to a class of medicines known as antimetabolites. It works by interfering with DNA synthesis in rapidly dividing cancer cells, preventing them from growing and multiplying. By disrupting the cancer cell cycle, Gemcitabine helps slow disease progression and supports effective cancer management.
Cancer develops when abnormal cells grow uncontrollably and spread to surrounding tissues or distant organs. These cancer cells depend on continuous DNA replication for survival and expansion. GEMLIEVA RTU 200 MG targets this process by incorporating itself into the DNA of malignant cells and blocking further replication, ultimately leading to cancer cell death.
GEMLIEVA RTU 200 MG is widely used in modern oncology and may be administered alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment plan.
The medicine is commonly prescribed for:
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Breast Cancer
Ovarian Cancer
Bladder Cancer
Biliary Tract Cancer
Metastatic Solid Tumors
Advanced Cancer Treatment Programs
Combination Chemotherapy Regimens
Gemcitabine has become an important part of cancer treatment worldwide because of its proven clinical effectiveness and broad range of therapeutic applications. It is frequently used in both first-line and subsequent treatment settings for several cancer types.
Manufactured under strict pharmaceutical quality standards, GEMLIEVA RTU 200 MG is designed to provide consistent quality, safety, and therapeutic performance.
Patients receiving Gemcitabine therapy typically require regular blood tests, liver and kidney function assessments, and routine medical evaluations to ensure treatment safety and effectiveness.
Due to its established role in oncology care, GEMLIEVA RTU 200 MG remains a trusted treatment option for patients undergoing chemotherapy for various cancers.
View Details
Pomalidomide Capsules 4mg
IMNOLIEVA 4 MG (Pomalidomide Capsules 4 mg) is a prescription anticancer medicine containing Pomalidomide 4 mg, an immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Pomalidomide belongs to a class of medicines known as Immunomodulatory Drugs (IMiDs) and works by helping the immune system fight cancer while also directly inhibiting the growth and survival of malignant cells.
Multiple Myeloma develops when abnormal plasma cells multiply uncontrollably within the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, and affect kidney function. Pomalidomide helps slow disease progression by targeting multiple pathways involved in cancer growth, immune regulation, and blood vessel formation that support tumor development.
IMNOLIEVA 4 MG is commonly prescribed for patients whose disease has returned after previous treatment or has become resistant to other therapies. It is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment strategies recommended by hematologists and oncologists.
Unlike conventional chemotherapy, Pomalidomide has a unique mechanism that combines direct anticancer effects with immune system modulation. This dual action makes it an important treatment option in modern multiple myeloma management.
IMNOLIEVA 4 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Advanced Plasma Cell Disorders
Combination Cancer Therapy Programs
Long-Term Hematology Treatment Plans
Immunomodulatory Cancer Treatment
Specialized Oncology Care
The medicine is widely used in modern hematology and oncology practice and has become an essential component of treatment strategies for patients with relapsed or treatment-resistant multiple myeloma.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 4 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical monitoring, including complete blood counts, liver and kidney function tests, and routine clinical evaluations to ensure optimal treatment outcomes and patient safety.
Due to its proven effectiveness and unique immunomodulatory properties, IMNOLIEVA 4 MG remains an important treatment option in advanced multiple myeloma care worldwide.
View Details
Pomalidomide Capsules 2mg
IMNOLIEVA 2 MG (Pomalidomide Capsules 2 mg) is a prescription anticancer medication containing Pomalidomide 2 mg, an advanced immunomodulatory agent used primarily in the treatment of Multiple Myeloma, a cancer that develops in plasma cells within the bone marrow. Pomalidomide belongs to a group of medicines known as Immunomodulatory Drugs (IMiDs), which help strengthen the body's immune response against cancer cells while directly inhibiting tumor growth and survival.
Multiple Myeloma occurs when abnormal plasma cells multiply uncontrollably in the bone marrow. These cancerous cells can interfere with the production of healthy blood cells, weaken bones, increase the risk of infections, and affect kidney function. Pomalidomide helps manage the disease by targeting several pathways involved in cancer cell growth, immune system regulation, and tumor development.
IMNOLIEVA 2 MG is commonly prescribed for patients with relapsed or refractory Multiple Myeloma, particularly when previous treatments have not produced the desired results or when the disease returns after earlier therapy. The medicine is often used in combination with other anticancer medicines and corticosteroids as part of comprehensive treatment regimens developed by hematologists and oncologists.
Unlike traditional chemotherapy, Pomalidomide offers a targeted and immune-based approach to cancer treatment. It helps activate specific immune cells, suppresses cancer cell growth, and reduces the formation of new blood vessels that tumors require for continued growth.
IMNOLIEVA 2 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Plasma Cell Disorders
Advanced Blood Cancer Management
Combination Oncology Treatment Programs
Long-Term Hematology Care
Immunomodulatory Cancer Therapy
The medicine has become an important component of modern blood cancer treatment and is widely used in specialized oncology and hematology centers worldwide.
Manufactured according to strict pharmaceutical quality standards, IMNOLIEVA 2 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pomalidomide therapy require regular medical supervision, including blood tests, liver function monitoring, kidney assessments, and routine clinical evaluations to ensure optimal treatment outcomes.
Due to its proven clinical effectiveness in managing advanced Multiple Myeloma, IMNOLIEVA 2 MG remains a trusted option in modern cancer care.
View Details
Capecitabine Tablets IP 500mg
CAPELIEVA 500 MG (Capecitabine Tablets IP 500 mg) is a prescription anticancer medicine containing Capecitabine 500 mg, an oral chemotherapy medication widely used for the treatment of various types of cancer, including colorectal cancer, breast cancer, gastric cancer, and other advanced solid tumors. Capecitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells.
Capecitabine is considered a prodrug, meaning it is converted inside the body into 5-Fluorouracil (5-FU), a well-established anticancer agent. This conversion occurs more actively within tumor tissues, helping target cancer cells while reducing exposure to healthy tissues. As a result, CAPELIEVA 500 MG offers the convenience of oral administration while delivering the proven benefits of fluoropyrimidine-based cancer therapy.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. CAPELIEVA 500 MG helps slow or stop this process by disrupting DNA synthesis in rapidly dividing cancer cells, thereby reducing tumor growth and progression.
The medicine is frequently prescribed as a standalone therapy or in combination with other chemotherapy agents, targeted therapies, or radiation treatment depending on the type and stage of cancer.
CAPELIEVA 500 MG is commonly prescribed for:
Colorectal Cancer
Metastatic Colorectal Cancer
Breast Cancer
Metastatic Breast Cancer
Gastric (Stomach) Cancer
Advanced Gastrointestinal Cancers
Combination Chemotherapy Regimens
Long-Term Oncology Treatment Programs
One of the key advantages of Capecitabine is that it allows patients to receive chemotherapy treatment at home under the supervision of their oncologist, reducing the need for frequent hospital-based infusions.
Manufactured according to strict pharmaceutical quality standards, CAPELIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Capecitabine therapy require regular medical monitoring, including blood tests, liver and kidney function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven clinical effectiveness and convenient oral administration, CAPELIEVA 500 MG remains an important component of modern cancer treatment worldwide.
View Details
Olaparib Tablets 150mg
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is a prescription targeted anticancer medicine containing Olaparib 150 mg, a highly advanced PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of several types of cancer associated with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Olaparib is widely used in modern precision oncology to help slow cancer growth, delay disease progression, and improve treatment outcomes in eligible patients.
Cancer cells with BRCA gene mutations often have difficulty repairing damaged DNA. PARIBLIEVA 150 MG works by blocking PARP enzymes, which cancer cells use to repair their DNA. When both repair mechanisms are disrupted, cancer cells are unable to survive and eventually die. This targeted approach allows Olaparib to selectively attack cancer cells while minimizing damage to healthy tissues.
PARIBLIEVA 150 MG has become an important treatment option in personalized cancer care and is commonly prescribed for patients whose tumors carry specific genetic abnormalities. Genetic testing is often performed before treatment to determine whether a patient is likely to benefit from Olaparib therapy.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Olaparib specifically targets cancer cells with defective DNA repair pathways. This precision-based mechanism has transformed the treatment landscape for several difficult-to-treat cancers.
PARIBLIEVA 150 MG is commonly prescribed for:
BRCA-Mutated Ovarian Cancer
Advanced Ovarian Cancer
Recurrent Ovarian Cancer
BRCA-Mutated Breast Cancer
HER2-Negative Breast Cancer with BRCA Mutation
Metastatic Breast Cancer
Pancreatic Cancer with BRCA Mutation
Metastatic Pancreatic Cancer
Prostate Cancer with Homologous Recombination Repair (HRR) Gene Mutations
Precision Oncology Treatment Programs
The medicine may be used as maintenance therapy after successful cancer treatment or as part of long-term disease management plans, depending on the patient's condition and oncologist’s recommendations.
Manufactured according to stringent pharmaceutical quality standards, PARIBLIEVA 150 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Olaparib therapy require routine monitoring, including blood tests, kidney and liver function assessments, and regular clinical evaluations to ensure safe and effective treatment.
Due to its targeted mechanism and proven clinical benefits, PARIBLIEVA 150 MG has become a valuable treatment option in modern cancer care worldwide.
View Details
Temozolomide Capsules IP 250mg
TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) is a prescription anticancer medicine containing Temozolomide 250 mg, an oral chemotherapy agent used primarily for the treatment of certain types of brain tumors. It belongs to a class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Brain tumors can be aggressive and difficult to treat due to their location and complex nature. Temozolomide has become an important component of modern neuro-oncology treatment because of its ability to cross the blood-brain barrier and directly target tumor cells within the brain. This unique characteristic makes it particularly effective in the management of specific malignant brain tumors.
TEMALIEVA 250 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), one of the most aggressive forms of brain cancer, and Anaplastic Astrocytoma, a malignant brain tumor arising from astrocyte cells. It may be used alone or in combination with radiation therapy and other treatment modalities as part of a comprehensive cancer management plan.
Unlike many traditional chemotherapy medicines that require intravenous administration, Temozolomide is available in capsule form, offering greater convenience and flexibility for patients undergoing long-term treatment.
The medicine is often prescribed during both initial treatment and maintenance therapy phases, depending on the patient’s diagnosis, treatment response, and oncologist's recommendations.
TEMALIEVA 250 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular blood tests, complete blood count monitoring, liver function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in brain cancer treatment, TEMALIEVA 250 MG has become a trusted option in modern oncology and neuro-oncology care worldwide.
View Details
Temozolomide Capsules IP 100 mg
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is a prescription anticancer medicine containing Temozolomide 100 mg, an oral chemotherapy drug widely used in the treatment of certain malignant brain tumors. It belongs to a class of medicines known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from growing, multiplying, and spreading.
Brain tumors are among the most complex cancers to treat due to their location within the central nervous system. One of the major advantages of Temozolomide is its ability to cross the blood-brain barrier, allowing it to directly target cancer cells within the brain. This characteristic has made Temozolomide a cornerstone treatment in modern neuro-oncology.
TEMALIEVA 100 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), the most aggressive type of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used as part of initial treatment, maintenance therapy, or recurrent tumor management depending on the patient's condition and oncologist's recommendations.
Unlike many traditional chemotherapy medicines that require intravenous administration, TEMALIEVA 100 MG is available in capsule form, making treatment more convenient for eligible patients while supporting long-term cancer management.
Temozolomide has become an important component of comprehensive brain cancer treatment programs because it can be used alone or alongside radiation therapy to improve disease control and treatment outcomes.
TEMALIEVA 100 MG is commonly prescribed for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular medical supervision, including complete blood count monitoring, liver function assessments, infection screening, and clinical evaluations to ensure safe and effective treatment.
Due to its proven effectiveness in brain tumor management, TEMALIEVA 100 MG has become a trusted treatment option in oncology centers worldwide.
View Details
Temozolomide Capsules IP 20mg
TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) is a prescription anticancer medicine containing Temozolomide 20 mg, an oral chemotherapy agent used in the treatment of specific malignant brain tumors. Temozolomide belongs to the class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells and preventing them from growing, multiplying, and spreading.
Temozolomide is widely recognized in neuro-oncology because of its unique ability to cross the blood-brain barrier, enabling it to reach and act directly on tumor cells within the brain. This characteristic makes it an important treatment option for patients with aggressive and difficult-to-treat brain cancers.
TEMALIEVA 20 MG is commonly prescribed for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used during initial treatment, maintenance therapy, or management of recurrent disease based on the patient’s condition and oncologist’s recommendations.
The 20 mg strength is often used as part of individualized dosing regimens, allowing oncologists to accurately adjust doses according to body surface area (BSA), treatment cycles, and patient-specific requirements.
Unlike intravenous chemotherapy, TEMALIEVA 20 MG is administered orally, providing convenience and flexibility while supporting long-term cancer treatment plans.
TEMALIEVA 20 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 20 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients undergoing Temozolomide treatment require regular blood count monitoring, liver function testing, and clinical evaluations to ensure safe and effective therapy.
Due to its established role in brain tumor treatment, TEMALIEVA 20 MG remains a valuable option in modern oncology and neuro-oncology care.
View Details
Lenalidomide Capsules 25mg
LENALIEVA 25 MG (Lenalidomide Capsules 25 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 25 mg, a highly effective treatment used for certain blood cancers and hematological disorders. It belongs to a class of medicines known as Immunomodulatory Agents (IMiDs) that help the body's immune system fight cancer cells while also inhibiting tumor growth and blood vessel formation.
Lenalidomide has become a cornerstone therapy in modern hematology and oncology due to its ability to target cancer cells through multiple mechanisms. It enhances immune cell activity, suppresses abnormal cell growth, and interferes with the development of blood vessels that tumors need to survive and spread.
LENALIEVA 25 MG is widely prescribed for patients with Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other blood-related cancers. It may be used alone or in combination with other anticancer therapies depending on the patient's condition and treatment plan.
The medicine is often recommended for long-term treatment and maintenance therapy to help control disease progression, improve treatment outcomes, and support prolonged remission in eligible patients.
LENALIEVA 25 MG is commonly prescribed for:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Maintenance Therapy Programs
Advanced Hematology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood tests, complete blood count monitoring, kidney function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in blood cancer management, LENALIEVA 25 MG has become an essential medicine in modern oncology and hematology practice worldwide.
View Details
Lenalidomide Capsules 10mg
LENALIEVA 10 MG (Lenalidomide Capsules 10 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 10 mg, a widely used treatment for specific blood cancers and bone marrow disorders. It belongs to the class of medicines known as Immunomodulatory Agents (IMiDs), which work by enhancing the body's immune response against cancer cells, inhibiting abnormal cell growth, and reducing the formation of blood vessels that support tumor development.
Lenalidomide has become a key component of modern hematology and oncology treatment protocols due to its ability to target cancer through multiple mechanisms. It helps strengthen immune system activity, suppresses cancer cell proliferation, and interferes with the microenvironment that allows cancer cells to survive and spread.
LENALIEVA 10 MG is commonly prescribed for the treatment of Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other hematological malignancies. It may be used as part of combination therapy or maintenance treatment depending on the patient's condition and clinical requirements.
The 10 mg strength is frequently used for individualized treatment plans, dose adjustments, maintenance therapy, and patients requiring lower doses based on treatment response or kidney function.
LENALIEVA 10 MG is commonly prescribed for:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Maintenance Therapy After Multiple Myeloma Treatment
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Long-Term Blood Cancer Management
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood count monitoring, kidney function testing, liver assessments, and routine clinical evaluations to ensure optimal treatment outcomes and safety.
Due to its proven efficacy and versatile clinical applications, LENALIEVA 10 MG remains an important medicine in modern hematology and oncology care.
View Details
Lenalidomide Capsules 5mg
LENALIEVA 5 MG (Lenalidomide Capsules 5 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 5 mg, used in the treatment of certain blood cancers and bone marrow disorders. Lenalidomide belongs to a class of medicines known as Immunomodulatory Drugs (IMiDs), which help the immune system identify and attack abnormal cells while also inhibiting cancer cell growth and reducing the formation of blood vessels that support tumor development.
Lenalidomide plays an important role in modern hematology and oncology by targeting cancer through multiple pathways. It enhances immune function, suppresses the growth of abnormal cells, promotes cancer cell death, and interferes with the tumor microenvironment that enables disease progression.
LENALIEVA 5 MG is widely prescribed for patients with Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, and Mantle Cell Lymphoma (MCL). It may be used alone or in combination with other therapies depending on the patient's diagnosis, treatment stage, and clinical requirements.
The 5 mg strength is commonly used for maintenance therapy, dose adjustments, elderly patients, and individuals requiring lower doses due to kidney impairment or treatment-related side effects. It allows oncologists to tailor therapy according to each patient's specific needs.
LENALIEVA 5 MG is commonly prescribed for:
Multiple Myeloma
Maintenance Therapy After Multiple Myeloma Treatment
Relapsed or Refractory Multiple Myeloma
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Long-Term Blood Cancer Management
Individualized Lenalidomide Therapy Programs
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 5 MG is designed to deliver consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood count monitoring, kidney function tests, liver assessments, and routine medical evaluations to ensure optimal treatment outcomes and safety.
Due to its established clinical benefits, LENALIEVA 5 MG remains an important component of modern blood cancer treatment strategies.
View Details
